Naturally acquired immunity against human papillomavirus (HPV): Why it matters in the HPV vaccine era

Journal of Infectious Diseases

Volumn 210, Issue 4, 2014, Pages 507-509

  Franceschi, Silvia ^a   Baussano, Iacopo ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Antibodies; HPV; HPV vaccine; Immunity; Mathematical models

Indexed keywords

CAPSID PROTEIN L1; HUMAN PAPILLOMAVIRUS 16 ANTIBODY; HUMAN PAPILLOMAVIRUS 18 ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY TITER; CANCER GRADING; CANCER RISK; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INCIDENCE; INNATE IMMUNITY; MULTICENTER STUDY (TOPIC); NOTE; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEROPREVALENCE; SEX DIFFERENCE; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS LIKE PARTICLE BASED ENZYME LINKED IMMUNOSORBENT ASSAY;

ANTIBODIES; HPV; HPV VACCINE; IMMUNITY; MATHEMATICAL MODELS;

ANTIBODIES, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84905582106     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu143     Document Type: Note

References (35)

1. Tindle RW. Immune evasion in human papillomavirus- associated cervical cancer. Nature Rev Cancer 2002; 2: 59-65.
2. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9.
3. Schiffman M, Safaeian M, Wentzensen N. The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis 2009; 36: 675-9.
4. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102: 1653-62.
5. Lin SW, Ghosh A, Porras C, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One 2013; 8: e53067.
6. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003- 2004. J Infect Dis 2009; 200: 1059-67.
7. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006; 119: 2612-9.
8. Castellsagué X, Naud P, Chow SN, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. 2014; 210: 517-34.
9. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011; 204: 94-102.
10. Vaccarella S, Franceschi S, Clifford GM, et al. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010; 19: 2379-88.
11. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115, 789 HPVpositive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
12. Lu B, Viscidi RP, Wu Y, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2012; 72: 676-85.
13. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16: 1874-9.
14. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. 2002; 13: 631-9.
15. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
16. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: e138.
17. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010; 28: 4091-102.
18. Baussano I, Garnett G, Segnan N, Ronco G, Vineis P. Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine 2011; 29: 1270-7.
19. Korostil IA, Ali H, Guy RJ, Donovan B, Law MG, Regan DG. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex Transm Dis 2013; 40: 833-5.
20. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-23.
21. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010; 26: 183-91.
22. Vanni T, Mendes Luz P, Foss A, Mesa-Frias M, Legood R. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. Vaccine 2012; 30: 4866-71.
23. Ribassin-Majed L, Lounes R, Clemencon S. Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies. PLoS One 2012; 7: e32251.
24. Turner HC, Baussano I, Garnett GP. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PLoS One 2013; 8: e75552.
25. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97: 1322-8.
26. Van de Velde N, BrissonM, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative modelbased analysis. Vaccine 2010; 28: 5473-84.
27. Baussano I, Elfstrom KM, Lazzarato F, et al. Type-specific human papillomavirus biological features: validated model-based estimates. PLoS One 2013; 8: e81171.
28. Bogaards JA, Xiridou M, Coupe VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection- induced resistance from the agedependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 2010; 171: 817-25.
29. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009; 27: 5133-41.
30. Johnson HC, Elfstrom KM, Edmunds WJ. Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach. PLoS One 2012; 7: e49614.
31. Tully SP, Anonychuk AM, Sanchez DM, Galvani AP, Bauch CT. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine 2012; 30: 425-35.
32. Vanska S, Auranen K, Leino T, et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One 2013; 8: e72088.
33. Baussano I, Ronco G, Segnan N, French K, Vineis P, Garnett GP. HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions. Epidemics 2010; 2: 21-8.
34. Baussano I, Franceschi S, Plummer M. Infection transmission and chronic disease models in the study of infection-associated cancers. Br J Cancer 2014; 110: 7-11.
35. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191 (suppl 1): S97-106.